会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • (2-Oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl) oxyalkylamides
properties having phosphodiosterase inhibiting
    • (2-氧代-1,2,3,5-四氢咪唑并[2,1-B]喹唑啉基)氧烷基酰胺性质,其具有磷酸二酯酶抑制
    • US4690925A
    • 1987-09-01
    • US734633
    • 1985-05-15
    • John H. FriedMichael C. Venuti
    • John H. FriedMichael C. Venuti
    • A61K31/505A61P7/02A61P9/00A61P35/00A61P43/00C07C205/44C07C205/56C07D487/04C12N9/99
    • C07D487/04C07C205/44C07C205/56
    • Compounds according to the formula ##STR1## , its optical isomers, or a pharmaceutically acceptable salt thereof wherein:m and n are integers of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbons;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 are combined to form an oxo group;R.sub.3 is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its aliphatic acylates of 1 to 6 carbon atoms or aryl acylates of 7 to 12 carbon atoms, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or .alpha.-amino acid side chains;R.sub.4 is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl;R.sub.5 is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a lower alkyl, lower alkoxy, --OH, --OCOR.sub.6, halo, --NH.sub.2, --N(R.sub.6).sub.2, --NHCOR.sub.6, --COOH, or --COO(R.sub.6) group wherein R.sub.6 is lower alkyl; phenyl or phenyl lower alkyl wherein phenyl is unsubstituted or substituted with 1 or more lower alkyl, halo or lower alkoxy groups or an --NH.sub.2, --N(R.sub.6).sub.2, --NHCOR.sub.6, --COOH, or --COOR.sub.6 group wherein R.sub.6 is lower alkyl;Y is hydrogen, alkyl of 1 to 4 carbon atoms, halo or lower alkoxy; andZ is --OR.sub.7 or --NR.sub.7 R.sub.8 wherein R.sub.7 and R.sub.8 are independently hydrogen or lower alkyl.
    • 式(I)的化合物,其旋光异构体或其药学上可接受的盐,其中:m和n为1至6的整数; R1是氢或1至4个碳的烷基; R2是氢或R1和R2组合形成氧代基团; R3为氢,1-6个碳原子的烷基,苯基,苄基,羟基低级烷基及其1至6个碳原子的脂族酰化物或7至12个碳原子的芳基酰化物,氨基甲酰基烷基,羧基烷基,烷氧基羰基烷基或α-氨基酸侧 链条 R4是氢,1-6个碳原子的烷基,苄基或羟基低级烷基; R5是氢,1至6个碳原子的烷基,3至8个碳原子的环烷基或4-12个碳原子的环烷基低级烷基,其中环烷基环是未取代的或被低级烷基,低级烷氧基,-OH,-OCOR6 ,卤素,-NH 2,-N(R 6)2,-NHCOR 6,-COOH或-COO(R 6)基团,其中R 6是低级烷基; 苯基或苯基低级烷基,其中苯基未被取代或被1个或多个低级烷基,卤代或低级烷氧基或-NH 2,-N(R 6)2,-NHCOR 6,-COOH或-COOR 6基团取代,其中R 6是低级烷基 ; Y是氢,1-4个碳原子的烷基,卤代或低级烷氧基; 并且Z是-OR 7或-NR 7 R 8,其中R 7和R 8独立地是氢或低级烷基。
    • 6. 发明授权
    • 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives
having anthelmintic activity
    • 5(6)具有驱虫活性的苯并环取代的苯并咪唑-2-氨基甲酸酯衍生物
    • US3993768A
    • 1976-11-23
    • US604502
    • 1975-08-13
    • Colin C. BeardJohn A. EdwardsJohn H. Fried
    • Colin C. BeardJohn A. EdwardsJohn H. Fried
    • C07D235/32
    • C07D235/32
    • This application describes further species embraced by the following generic formula: ##SPC1##Where R is a lower alkyl group having 1 to 4 carbon atoms; R.sup.1 is --SOR.sup.2, --SO.sub.2 R.sup.2, --SCN, --SR.sup.5, --OR.sup.5 or M'(CH.sub.2).sub.n MR.sup.7 where M and M' are independently ##EQU1## R.sup.7 is lower alkyl having 1 to 4 carbon atoms or aryl, and n is 1-4; R.sup.2 is lower alkyl having from 1 to 6 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, lower alkenyl or lower alkynyl having 3 to 6 carbon atoms, or aralkyl or aryl; R.sup.5 is lower alkenyl, lower alkynyl, or aralkyl; and the R.sup.1 substitution is at the 5(6)-position. The above compounds can also be substituted at the 1-position.
    • 本申请描述了由以下通式表示的其它物质:+ q,10,其中R是具有1至4个碳原子的低级烷基; R 1是-SOR 2,-SO 2 R 2,-SCN,-SR 5,-OR 5或M'(CH 2)nMR 7,其中M和M'独立地为O和R a,O,S,S,S和R d' 4个碳原子或芳基,n为1-4; R2是具有1至6个碳原子的低级烷基,具有3至7个碳原子的环烷基,具有3至6个碳原子的低级链烯基或低级炔基,或芳烷基或芳基; R5是低级烯基,低级炔基或芳烷基; 而R1取代位于5(6)位。 上述化合物也可以在1-位取代。
    • 9. 发明授权
    • .beta.-Adrenergic blocking agents in the 1,2,3-thiadiazole series
    • {62-在1,2,3-噻二唑系列中的肾上腺素能阻断剂
    • US3940407A
    • 1976-02-24
    • US506659
    • 1974-09-16
    • Joseph M. MuchowskiJohn H. Fried
    • Joseph M. MuchowskiJohn H. Fried
    • C07C45/54C07C45/64C07D285/06
    • C07D285/06C07C205/45C07C45/54C07C45/64
    • Novel 4-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]- and 5-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]-1,2,3-thiadiazole derivatives which may be further substituted at the C-5 or C-4 position of the thiadiazole ring, respectively, by a lower alkyl, phenyl, trifluoromethyl, carboxy, alkoxycarbonyl, cyano or an aminocarbonyl group, and the pharmaceutically acceptable acid addition salts thereof and processes for the production of such compounds; 4-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole and 5-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole are representative of the class. These compounds possess cardiovascular activity and are useful for the treatment of abnormal heart conditions in mammals.
    • 4- [2,3或4(3-氨基-2-羟丙氧基)苯基]和5- [2,3或4(3-氨基-2-羟基丙氧基)苯基] -1,2,3-噻二唑衍生物 其可以在噻二唑环的C-5或C-4位被低级烷基,苯基,三氟甲基,羧基,烷氧基羰基,氰基或氨基羰基进一步取代,及其药学上可接受的酸加成盐和 生产这些化合物的方法; 4- [4-(3-叔丁基氨基-2-羟基丙氧基)苯基] -1,2,3-噻二唑和5- [4(3-叔丁基氨基-2-羟基丙氧基)苯基] 噻二唑是该类的代表。 这些化合物具有心血管活性,可用于治疗哺乳动物异常心脏病。